Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 27 of 27 publications.

Eiden AL, Hartley L, Garbinsky D, Saande C, Russo J, Gabriel MH, Price M, Bhatti A. Adult vaccination coverage in the United States: a database analysis and literature review of improvement strategies. Hum Vaccin Immunother. 2024 Dec 31;20(1):2381283. doi: 10.1080/21645515.2024.2381283

La EM, Bunniran S, Garbinsky D, Reynolds M, Schwab P, Poston S, Harrington L. Respiratory syncytial virus knowledge, attitudes, and perceptions among adults in the United States. Hum Vaccin Immunother. 2023 Dec 31;20(1):2303796. doi: 10.1080/21645515.2024.2303796

Curran D, Patterson BJ, Carrico J, Salem A, La EM, Lorenc Stephane, Hicks KA, Poston S, Carpenter CF. Public health impact of recombinant zoster vaccine for prevention of herpes zoster in US adults immunocompromised due to cancer. Hum Vaccin Immunother. 2023 Dec 31;19(1):2167907. doi: 10.1080/21645515.2023.2167907

Marriott BR, Walker MR, Howard J, Puspitasari A, Scott K, Albright K, Lewis CC. Taking a magnifying glass to measurement-based care consultation sessions: with what issues do mental health clinicians struggle? Adm Policy Ment Health. 2023 May;50(3):366-78. doi: 10.1007/s10488-022-01244-9

Herrera-Restrepo O, Ghaswalla P, Davis K, Sweeney C, Davenport E, Trofa A, Buck PM. Hepatitis A and Hepatitis B vaccination in adult patients at risk: a survey of US healthcare providers' attitudes and practices. Hum Vaccin Immunother. 2022 Nov 30;18(6):2123180. doi: 10.1080/21645515.2022.2123180

Herrera-Restrepo O, Davis K, Sweeney C, Davenport E, Ghaswalla P, Buck PO. Hepatitis A and B vaccination in adults at risk: a survey of US healthcare providers' attitudes and practices. Hum Vaccin Immunother. 2022 Nov 30;18(6):2123180. doi: 10.1080/21645515.2022.2123180

Poirrier JE, DeMartino JK, Nagar S, Carrico J, Hicks K, Meyers J, Stoddard J. Burden of opioid use for pain management among adult herpes zoster patients in the US and the potential impact of vaccination. Hum Vaccin Immunother. 2022 Nov;18(5):2040328. doi: 10.1080/21645515.2022.2040328

Carrasquilla G, Porras-Ramirez A, Martinez S, DeAntonio R, Devadiga R, Talarico C, Caceres DC, Castrejon MM, Juliao P. Trends in all-cause pneumonia and otitis media in children aged <2 years following pneumococcal conjugate vaccine introduction in Colombia. Hum Vaccin Immunother. 2021 Apr 3;17(4):1173-80. doi: 10.1080/21645515.2020.1805990

Talbird SE, La EM, Carrico J, Poston S, Poirrier JE, DeMartino JK, Hogea CS. Impact of population aging on the burden of vaccine-preventable diseases among older adults in the United States. Hum Vaccin Immunother. 2020 Aug 6;1-12. doi: 10.1080/21645515.2020.1780847

Graham J, Wolfson LJ, Kyle J, Perez Bolde-Villarreal C, Guarneros-DeRegil DB, Monsanto H, Pillsbury M, Talbird S, Daniels VJ. Budget impact analysis of multiple varicella vaccination strategies: a Mexico perspective. Hum Vaccin Immunother. 2019 Dec 18;16(4):886-94. doi: 10.1080/21645515.2019.1672491

La EM, Talbird SE, Kanadanian KV, Huang L, Fain J, Srivastava A. Cost calculator for mass vaccination response to a US college campus outbreak of serogroup B meningococcal disease. Hum Vaccin Immunother. 2019 Apr 3;15(4):978-86. doi: 10.1080/21645515.2018.1556074

Curran D, Patterson BJ, Van-Oorschot D, Buck PO, Carrico J, Hicks KA, Lee B, Yawn BP. Cost-effectiveness of an adjuvanted recombinant zoster vaccine in older adults in the United States who have been previously vaccinated with zoster vaccine live. Hum Vaccin Immunother. 2019;15(4):765-71. doi: 10.1080/21645515.2018.1558689.

Luna-Casas G, Juliao P, Carreno-Manjarrez R, Castaneda-Prado A, Cervantes-Apolinar MY, Navarro-Rodriguez R, Sanchez-Gonzalez G, Cortes-Alcala R, DeAntonio R. Vaccine coverage and compliance in Mexico with the two-dose and three-dose rotavirus vaccines. Hum Vaccin Immunother. 2019;15(6):1251-9. doi: 10.1080/21645515.2018.1540827

Wasserman M, Palacios MG, Grajales AG, Berenice Baez-Revueltas F, Wilson M, McDade C, Farkouh R. Modeling the sustained use of the 13-valent pneumococcal conjugate vaccine compared to switching to the 10-valent vaccine in Mexico. Hum Vaccin Immunother. 2019;15(3):560-9. doi: 10.1080/21645515.2018.1516491

Hoffman V, Abu-Elyazeed R, Enger C, Esposito DB, Doherty MC, Quinlan SC, Skerry K, Holick CN, Basile P, Friedland LR, Praet N, Wery S, Willame C, Dore DD, Rosillon D. Safety study of live, oral human rotavirus vaccine: a cohort study in United States health insurance plans. Hum Vaccin Immunother. 2018 Jul 3;14(7):1782-90. doi: 10.1080/21645515.2018.1450123

Wilson M, Lucas A, Cameron A, Luo M. Budget impact of adding vedolizumab to a health plan formulary as a first-line biologic option for ulcerative colitis and crohn's disease. Am Health Drug Benefits. 2018 Jul;11(5):253-62.

La EM, Trantham L, Kurosky SK, Odom D, Aris E, Hogea C. An analysis of factors associated with influenza, pneumoccocal, Tdap, and herpes zoster vaccine uptake in the US adult population and corresponding inter-state variability. Hum Vaccin Immunother. 2018 Feb 1;14(2):430-41. doi: 10.1080/21645515.2017.1403697

Kurosky SK, Davis KL, Krishnarajah G. Effect of combination vaccines on completion and compliance of childhood vaccinations in the United States. Hum Vaccin Immunother. 2017 Nov;2(13):2494-502. doi: 10.1080/21645515.2017.1362515

Meyers JL, Madhwani S, Rausch D, Candrilli SD, Krishnarajah G, Yan S. Analysis of real-world health care costs among immunocompetent patients aged 50 years or older with herpes zoster in the United States. Hum Vaccin Immunother. 2017 Aug 3;13(8):1861-72.

Brogan AJ, Talbird SE, Davis AE, Thommes EW, Meier G. Cost-effectiveness of seasonal quadrivalent versus trivalent influenza vaccination in the United States: a dynamic transmission modeling approach. Hum Vaccin Immunother. 2017 Mar 4;13(3):533-42. doi: 10.1080/21645515.2016.1242541

Willame C, Rosillon D, Zima J, Angelo MG, Stuurman AL, Vroling H, Boggon R, Bunge EM, Pladevall-Vila M, Baril L. Risk of new onset autoimmune disease in 9- to 25-year-old women exposed to human papillomavirus-16/18 AS04-adjuvanted vaccine in the United Kingdom. Hum Vaccin Immunother. 2016 Nov;12(11):2862-71. doi: 10.1080/21645515.2016.1199308

Lopez-Vicente M, Forns J, Esnaola M, Suades-Gonzalez E, Alvarez-Pedrerol M, Robinson O, Julvez J, Garcia-Aymerich J, Sunye J. Physical activity and cognitive trajectories in schoolchildren. Pediatr Exerc Sci. 2016 Aug;91(8):770-5.

Harris JB, Ward MA, Schwab P. Is response-guided therapy being applied in the clinical setting? The hepatitis C example. Am Health Drug Benefits. 2015 Feb;8(1):22-8.

Karve SJ, Krishnarajah G, Korsnes JS, Cassidy A, Candrilli SD. Burden of acute gastroenteritis, norovirus and rotavirus in a managed care population. Hum Vaccin Immunother. 2014 Apr;10:1544-66. doi: 10.4161/hv.28704

Karve S, Misurski DA, Meier G, Davis KL. Employer-incurred health care costs and productivity losses associated with influenza. Hum Vaccin Immunother. 2013 Apr 1;9(4):841-57.

Sacco P, Capkun-Niggli G, Zhang X, Jose R. The economic burden of fragile x syndrome: healthcare resource utilization in the United States. Am Health Drug Benefits. 2013 Mar;6(2):73-83.

Lennert B, Bibeau W, Farrelly E, Sacco P, Schoor T. Assessment of treatment patterns and patient outcomes in levodopa-induced dyskinesias (ASTROID): a US chart review study. Am Health Drug Benefits. 2012 Sep;5(6):347-58.